ReviewBiosensors2025
Recent Advances in Electrochemical Biosensors for Neurodegenerative Disease Biomarkers.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Advancements in Nanomaterial-Based Biosensors for Neuropsychiatric and Neurodegenerative Diagnostics: From Biomarker Discovery to Clinical Translation.Biosensors · 2026Review
- Review
- Review
- A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?Analytical and bioanalytical chemistry · 2025Review
- Central Nervous System-Derived Extracellular Vesicles as Biomarkers in Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Polymer-Based Electrochemical Sensors for the Diagnosis of Neurodegenerative Diseases.Cellular and molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), represent a growing global health challenge with overlapping biomarkers. Key biomarkers, including α-synucleins, amyloid-β, and Tau proteins, are critical for accurate detection but are often assessed using conventional methods like enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR), which are invasive, costly, and time-intensive. Electrochemical biosensors have emerged as promising tools for biomarker detection due to their high sensitivity, rapid response, and potential for miniaturization. The integration of nanomaterials has further enhanced their performance, improving sensitivity, specificity, and practical application. To this end, this review provides a comprehensive overview of recent advances in electrochemical biosensors for detecting neurodegenerative disease biomarkers, highlighting their strengths, limitations, and future opportunities. By addressing the challenges of early diagnosis, this work aims to stimulate interdisciplinary innovation and improve clinical outcomes for neurodegenerative disease patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.